Literature DB >> 872495

Response optimization of drug dosage: antiarrhythmic studies with tocainide.

P J Meffin, R A Winkle, T F Blaschke, J Fitzgerald, D C Harrison, S R Harapat, P A Bell.   

Abstract

The benefits of using antiarrhythmic response to optimize dosage regimens of antiarrhythmic drugs in individual patients have been examined. Graded antiarrhythmic response and simultaneously measured plasma drug concentrations have been obtained in 15 patients receiving multiple oral doses of a new antiarrhythmic, tocainide. Plasma drug concentration-antiarrhythmic response data from each of 11 subjects responding to the drug have been fitted by a generalized concentration effect function which is valid over the entire range of response. With the use of experimentally determined pharmacokinetic parameters to define the dose-plasma concentration relationship and plasma drug concentration-response parameters estimated for individual patients, simulations were carried out to show the effect of various dosage regimens on antiarrhythmic response in individual patients. Such simulations provide a means of assessing antiarrhythmic effect in the range of clinical interest (80% to 100% of maximum effect), where the antiarrhythmic effect is a nonlinear function of dose, plasma drug concentration, or their logarithms. The simulations also demonstrate that for identical daily doses and dosing intervals patients show marked variability in antiarrhythmic response.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 872495     DOI: 10.1002/cpt197722142

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Efficacy and tolerance of tocainide during acute and long-term treatment of chronic ventricular arrhythmias.

Authors:  C Sonnhag
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

3.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Modeling of drug response in individual subjects.

Authors:  A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

Review 6.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

7.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 8.  Tocainide. A review of its pharmacological properties and therapeutic efficacy.

Authors:  B Holmes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-08       Impact factor: 9.546

Review 9.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

10.  Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man.

Authors:  D M Cocchetto; S M Owens; M Perez-Reyes; S DiGuiseppi; L L Miller
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.